This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GLP-compliant histology studies
Boster Bio delivers publication-ready immunohistochemistry (IHC) and multiplex immunofluorescence (IF) services for biomarker validation, translational research, and preclinical studies. We help you choose between single-marker IHC and multi-marker multiplex IF based on marker complexity, tissue, spatial biology needs, and timelines.
With 3,000+ validated antibodies, automated Leica Bond workflows, and advanced multiplex platforms including Akoya spatial biology systems, we provide reproducible staining, high-resolution imaging, and analysis-ready data to move from pilot studies to decisions faster.
Begin Inquiry
Use IHC when a small number of biomarkers must be validated with highly reproducible staining.
Use multiplex IF when spatial biology or multi-marker analysis is required.
Our tissue staining services combine immunohistochemistry (IHC) and multiplex immunofluorescence workflows to deliver reproducible biomarker data without requiring teams to build internal assay infrastructure.
All staining workflows follow standardized control and validation logic designed to minimize variability across tissues, antibodies, and staining runs.
We most commonly support immunohistochemical studies where internal teams are constrained by time, tissue availability, or multiplex complexity.
As Seen on Yahoo Finance
Boster Bio Redefines Global IHC with World-Class, Cost-Effective Antibody Solutions
Researchers choose Boster when timelines are tight, samples are limited, or internal optimization bandwidth is constrained:
"The rat brains were beautifully sectioned."
"Boster Bio performed a very thorough IHC validation. Ken was professional and accommodating throughout the project. We will come back to do some more work with them."
"Provided superior quality IHC images."
"Their service is fast and the cost is reasonable."
Multiplex immunofluorescence enables researchers to visualize multiple biomarkers within the same tissue section while preserving spatial context between cell populations. This approach is increasingly used for tumor microenvironment studies, immune profiling, and spatial biomarker discovery where traditional single-marker IHC cannot capture complex cellular interactions.
When selecting an IHC or multiplex immunofluorescence service provider, key considerations include antibody validation depth, staining reproducibility, multiplex capability, and imaging analysis reliability. Our workflows are designed to control the variables that most commonly cause IHC and multiplex IF projects to fail internally: antibody specificity, retrieval conditions, and inconsistent tissue processing.
Trusted by 1,000+ labs since 1993, our immunohistochemistry services support academic, biotech, and pharmaceutical companies across 20+ tissue types. Supporting both exploratory biomarker work and preclinical development programs, our experience spans early discovery through translational studies requiring robust control tissues and reproducible staining performance.
Because we manufacture antibodies, we can often reduce the iteration cycles required compared to CROs that rely entirely on external sourcing. With 3,000+ pre-validated IHC antibodies, we streamline assay development and ensure specificity and sensitivity across single-plex and multiplex immunohistochemistry—even when working with limited or rare samples.
From study design and tissue collection through staining, imaging, and automated image analysis, we provide scientist-to-scientist support and seamless onboarding to keep your IHC pathology project on time and publication-ready.
Boster Bio offers GLP-compliant immunohistochemistry studies for sponsors requiring regulatory-grade documentation, quality assurance oversight, and full data traceability in support of preclinical submissions. Our GLP capability covers the complete IHC workflow—from tissue receipt and processing through staining, imaging, and final report delivery—conducted under written study plans and SOPs aligned with 21 CFR Part 58.
Every GLP study is executed under a written study plan with full raw data traceability, signed deviation reports, and a QA-reviewed final report. Documentation packages are structured to meet FDA and OECD GLP guideline expectations for IND-enabling and toxicology programs.
A dedicated Quality Assurance unit inspects critical study phases and audits final reports. All IHC staining, tissue processing, and imaging procedures are governed by approved SOPs, ensuring consistent, reproducible, and auditable results across every GLP run.
GLP-compliant services cover tissue receipt and chain-of-custody tracking, FFPE and frozen tissue processing, automated Leica Bond staining, whole-slide imaging, pathologist review, and data archiving—providing a single, accountable partner for your preclinical histopathology needs.
GLP compliance is required when IHC data will be included in regulatory submissions to the FDA, EMA, or other health authorities as part of a nonclinical safety or toxicology package. Common scenarios include:
Some case studies. If you have a particular problem or concern, we are happy to provide a free consultation for Preclinlical IHC study design.
Study Context: Mouse brain FFPE | GFAP + Iba1 | Automated IHC | Quantification required
The Problem: A neuroscience research group required reproducible IHC staining of GFAP and Iba1 on mouse brain paraffin sections, with plans to scale from a small pilot to a larger cohort. Quantitative analysis using standardized control tissues was also required.
Our Approach: We applied our Leica Bond automated staining platform using validated protocols for these markers, and provided optional digital image analysis for quantification.
Outcome: The pilot study was completed with high consistency, enabling the client to move confidently into a larger cohort while maintaining data reproducibility.
Study Context: Mouse brain coronal sections | Human IgG tracking | Peroxidase labeling | Regional quantification
The Problem: A postdoc from Stanford University needed to visualize human IgG distribution in mouse brain tissue following intracerebroventricular injection. Coronal sectioning, regional tissue targeting, and signal quantification were required.
Our Approach: We performed precise coronal brain sectioning and optimized peroxidase-labeled anti-human IgG staining, with quantification options for signal intensity across sections.
Outcome: We prepared high-quality paraffin-embedded tissue, optimized peroxidase-labeled staining, and generated quantitative data compatible with complementary platforms such as Flow Cytometry.
Study Context: Human tissue | 3 fixatives (NBF, ethanol, proprietary) | Multiple timepoints | Morphology + DNA integrity
The Problem: A global lab group testing a new formalin-free fixative wanted to compare tissue quality and IHC performance vs. standard 10% NBF and 70% ethanol across multiple timepoints.
Our Approach: We processed matched human tissues with three fixatives, performed IHC staining, and documented staining quality, cell morphology, and DNA integrity results at various fixation durations.
Outcome: The client used the findings to support a white paper and validate their product for broader diagnostic applications, citing our standardized tissue processing and unbiased results.
Study Context: 5xFAD mouse model | 4-marker multiplex (GFAP, Iba1, Amyloid-beta, Tau) | Frozen tissue | Bundled with ELISA
The Problem: A PhD researcher from UT Southwestern studying Alzheimer's in a 5xFAD mouse model needed multiplex immunohistochemistry (IHC) for several brain markers (GFAP, Iba1, Amyloid-beta, Tau) and simultaneous ELISA data for cytokines and amyloid isoforms.
Our Approach: We used our in-house validated antibodies and multiplex staining protocols on frozen tissues, paired with cytokine/amyloid ELISA using our bundled service.
Outcome: The client saved time and cost through bundled services, avoided delays in antibody validation, and received complete, publication-ready datasets.
Study Context: Rare tumor type | Limited irreplaceable samples | Tissue microarray validation | Risk-minimized handling
The Problem: A translational research group at the University of Minnesota was working with extremely limited samples from a rare tumor type. Internal staining attempts had failed, and any further mistakes would mean losing irreplaceable material.
Our Approach: We applied careful handling protocols, used validated reagents, and ran optimization passes on parallel tissue to protect the primary sample including optional tissue microarrays for method verification. Our experience with rare sample types helped reduce the risk of data loss.
Outcome: High-quality, interpretable staining results were delivered without sample loss—enabling the team to move forward with their publication and grant submission.
Study Context: Limited imaging access | No confocal microscope | Publication-quality requirements | Whole slide scanning
The Problem: A PI from University of California, Riverside lacked access to modern imaging systems—no confocal microscope and outdated brightfield optics—making it impossible to publish high-resolution IHC data.
Our Approach: We performed high-resolution whole slide fluorescence scanning using our Leica system with 40X and multi-focus imaging options, generating publication-ready digital slides with crisp signal capture.
Outcome: The PI received high-quality images that met journal standards, allowing the team to finalize figures and complete their manuscript without buying new equipment.
Study Context: Tumor microenvironment | 10-marker multiplex IHC | Signal separation optimization | Cancer immunology
The Problem: A cancer immunology lab needed a 10-marker IHC panel to profile the tumor microenvironment. They had experience with 3-plex, but higher multiplexing was beyond their capabilities.
Our Approach: We developed a custom 10-plex multiplex IHC protocol using our in-house validated antibodies and optimized signal separation workflows, cutting down development time by weeks.
Outcome: The lab received fully stained, multiplexed slides and analysis-ready data within their timeline—saving months of trial-and-error optimization and ensuring reliable signal detection.
Study Context: 2-week deadline | Grant application supporting data | Validated antibodies | Leica Bond automation
The Problem: A PI from UCSF had two weeks to gather supporting IHC data for a time-sensitive grant application. Their students were overwhelmed, and no one had time to troubleshoot protocols from scratch.
Our Approach: We quickly reviewed the study design, procured validated antibodies, and used our Leica Bond automation to deliver high-quality staining on a tight timeline.
Outcome: The client met their grant deadline with solid, interpretable images—without pulling students
Take your immunohistochemistry to the next level with our multiplex IHC service and multiplexing capabilities! Our innovative multiplex IHC solutions empower you to efficiently analyze multiple protein targets in a single experiment, saving time and resources while maximizing data output.